Skip to main content
Erschienen in: Clinical and Translational Oncology 7/2014

01.07.2014 | Research Article

Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells

verfasst von: J. Cai, S. Chen, W. Zhang, Y. Wei, J. Lu, J. Xing, Y. Dong

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

5-Fluorouracil (5-Fu) is a commonly used chemotherapeutic agent in clinical care of breast cancer patients. However, the mechanism of how the 5-Fu works is complex and still largely unknown.

Objective

The objective of this study was to understand the mechanism further and explore the new targets of 5-Fu.

Methods

The differentially expressed proteins induced by 5-Fu in human breast cancer MCF-7 cells were identified by proteomic analysis. Four differentially expressed proteins were validated using Western blot and quantitative real-time reverse-transcription polymerase chain reaction analysis for protein and mRNA levels. The effect of 5-Fu on MCF-7 cells was determined by cell viability assay, transmission electron microscopy and flow cytometry analysis.

Results

5-Fu dose-dependently inhibited cell proliferation with the IC50 value of 98.2 μM. 5-Fu also induced obviously morphological change and apoptosis in MCF-7 cells. Twelve differentially expressed proteins involved in energy metabolism, cytoskeleton, cellular signal transduction and tumor invasion and metastasis were identified.

Conclusion

These results may provide a new insight into the molecular mechanism of 5-Fu in therapy of breast cancer.
Literatur
1.
Zurück zum Zitat Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–6.PubMedCrossRef Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–6.PubMedCrossRef
2.
Zurück zum Zitat Chuang-Xin L, Wen-Yu W, Yao C, Xiao-Yan L, Yun Z. Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-kappaB. Oncol Lett. 2012;4:775–8.PubMedCentralPubMed Chuang-Xin L, Wen-Yu W, Yao C, Xiao-Yan L, Yun Z. Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-kappaB. Oncol Lett. 2012;4:775–8.PubMedCentralPubMed
3.
Zurück zum Zitat Gravalos C, Salut A, Garcia-Giron C, Garcia-Carbonero R, Leon AI, Sevilla I, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012;14:606–12.PubMedCentralPubMedCrossRef Gravalos C, Salut A, Garcia-Giron C, Garcia-Carbonero R, Leon AI, Sevilla I, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012;14:606–12.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Garrido-Laguna I, Amador ML, Ruiz J, Cortes-Funes H. Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clin Transl Oncol. 2009;11:183–5.PubMedCrossRef Garrido-Laguna I, Amador ML, Ruiz J, Cortes-Funes H. Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clin Transl Oncol. 2009;11:183–5.PubMedCrossRef
5.
Zurück zum Zitat Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381–95.PubMedCrossRef Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381–95.PubMedCrossRef
6.
7.
Zurück zum Zitat Ghosh AK, Steele R, Ray RB. c-Myc promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway. J Biol Chem. 2005;280:14325–30.PubMedCrossRef Ghosh AK, Steele R, Ray RB. c-Myc promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway. J Biol Chem. 2005;280:14325–30.PubMedCrossRef
8.
Zurück zum Zitat Ghosh AK, Majumder M, Steele R, Liu TJ, Ray RB. MBP-1 mediated apoptosis involves cytochrome c release from mitochondria. Oncogene. 2002;21:2775–84.PubMedCrossRef Ghosh AK, Majumder M, Steele R, Liu TJ, Ray RB. MBP-1 mediated apoptosis involves cytochrome c release from mitochondria. Oncogene. 2002;21:2775–84.PubMedCrossRef
9.
Zurück zum Zitat Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002;8:2298–305.PubMed Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002;8:2298–305.PubMed
10.
Zurück zum Zitat Roth U, Razawi H, Hommer J, Engelmann K, Schwientek T, Muller S, et al. Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma. Proteomics. 2010;10:194–202.PubMedCrossRef Roth U, Razawi H, Hommer J, Engelmann K, Schwientek T, Muller S, et al. Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma. Proteomics. 2010;10:194–202.PubMedCrossRef
11.
Zurück zum Zitat Liu X, Feng R, Du L. The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett. 2010;584:3185–92.PubMedCrossRef Liu X, Feng R, Du L. The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett. 2010;584:3185–92.PubMedCrossRef
13.
Zurück zum Zitat Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013;11:52.PubMedCentralPubMedCrossRef Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013;11:52.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Busch T, Armacki M, Eiseler T, Joodi G, Temme C, Jansen J, et al. Keratin 8 phosphorylation regulates keratin reorganization and migration of epithelial tumor cells. J Cell Sci. 2012;125:2148–59.PubMedCentralPubMedCrossRef Busch T, Armacki M, Eiseler T, Joodi G, Temme C, Jansen J, et al. Keratin 8 phosphorylation regulates keratin reorganization and migration of epithelial tumor cells. J Cell Sci. 2012;125:2148–59.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Wang H, Li W, Jin X, Cui S, Zhao L. LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. Eur J Cancer. 2013;49:974–83.PubMedCrossRef Wang H, Li W, Jin X, Cui S, Zhao L. LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. Eur J Cancer. 2013;49:974–83.PubMedCrossRef
16.
Zurück zum Zitat Martin S, Lamb HK, Brady C, Lefkove B, Bonner MY, Thompson P, et al. Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78. Br J Cancer. 2013;109:433–43.PubMedCrossRef Martin S, Lamb HK, Brady C, Lefkove B, Bonner MY, Thompson P, et al. Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78. Br J Cancer. 2013;109:433–43.PubMedCrossRef
17.
Zurück zum Zitat Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol. 2008;181:2533–43.PubMedCrossRef Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol. 2008;181:2533–43.PubMedCrossRef
18.
Zurück zum Zitat Greiner J, Schneider V, Schmitt M, Gotz M, Dohner K, Wiesneth M, et al. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood. 2013;122:1087–8.PubMedCrossRef Greiner J, Schneider V, Schmitt M, Gotz M, Dohner K, Wiesneth M, et al. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood. 2013;122:1087–8.PubMedCrossRef
19.
Zurück zum Zitat Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest. 2012;122:2554–66.PubMedCentralPubMedCrossRef Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang W, et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J Clin Invest. 2012;122:2554–66.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Cao XX, Xu JD, Liu XL, Xu JW, Wang WJ, Li QQ, et al. RACK1: a superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer. 2010;127:1172–9.PubMedCrossRef Cao XX, Xu JD, Liu XL, Xu JW, Wang WJ, Li QQ, et al. RACK1: a superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer. 2010;127:1172–9.PubMedCrossRef
21.
Zurück zum Zitat Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ. RACK1 is up-regulated in angiogenesis and human carcinomas. Faseb J. 2000;14:2549–58.PubMedCrossRef Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ. RACK1 is up-regulated in angiogenesis and human carcinomas. Faseb J. 2000;14:2549–58.PubMedCrossRef
22.
Zurück zum Zitat Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. Thyroid. 2011;21:1217–25.PubMedCrossRef Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. Thyroid. 2011;21:1217–25.PubMedCrossRef
23.
Zurück zum Zitat Wang Z, Zhang B, Jiang L, Zeng X, Chen Y, Feng X, et al. RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J Cancer. 2009;45:490–6.PubMedCrossRef Wang Z, Zhang B, Jiang L, Zeng X, Chen Y, Feng X, et al. RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J Cancer. 2009;45:490–6.PubMedCrossRef
24.
Zurück zum Zitat Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Shinichiro R, et al. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer. 2010;69:54–9.PubMedCrossRef Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Shinichiro R, et al. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer. 2010;69:54–9.PubMedCrossRef
Metadaten
Titel
Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells
verfasst von
J. Cai
S. Chen
W. Zhang
Y. Wei
J. Lu
J. Xing
Y. Dong
Publikationsdatum
01.07.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 7/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1127-9

Weitere Artikel der Ausgabe 7/2014

Clinical and Translational Oncology 7/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.